11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Phosphorylation status at Smad3 linker region modulates transforming growth factor‐β‐induced epithelial‐mesenchymal transition and cancer progression

      review-article
      1 , , 1 , 1 , 2 ,
      Cancer Science
      John Wiley and Sons Inc.
      breast cancer, EMT, metastasis, Smad3, TGF‐β

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Smad3, a major transcription factor in transforming growth factor‐β ( TGF‐β) signaling, plays critical roles in both tumor‐suppressive and pro‐oncogenic functions. Upon TGF‐β stimulation, the C‐terminal tail of Smad3 undergoes phosphorylation that is essential for canonical TGF‐β signaling. The Smad3 linker region contains serine/threonine phosphorylation sites and can be phosphorylated by intracellular kinases, such as the MAPK family, cyclin‐dependent kinase ( CDK) family and glycogen synthase kinase‐3β ( GSK‐3β). Previous reports based on cell culture studies by us and others showed that mutation of Smad3 linker phosphorylation sites dramatically intensifies TGF‐β responses as well as growth‐inhibitory function and epithelial‐mesenchymal transition (EMT), suggesting that Smad3 linker phosphorylation suppresses TGF‐β transcriptional activities. However, recent discoveries of Smad3‐interacting molecules that preferentially bind phosphorylated Smad3 linker serine/threonine residues have shown a multitude of signal transductions that either enhance or suppress TGF‐β responses associated with Smad3 turnover or cancer progression. This review aims at providing new insight into the perplexing mechanisms of TGF‐β signaling affected by Smad3 linker phosphorylation and further attempts to gain insight into elimination and protection of TGF‐β‐mediated oncogenic and growth‐suppressive signals, respectively.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Roles of TGFbeta in metastasis.

          The TGFbeta signaling pathway is conserved from flies to humans and has been shown to regulate such diverse processes as cell proliferation, differentiation, motility, adhesion, organization, and programmed cell death. Both in vitro and in vivo experiments suggest that TGFbeta can utilize these varied programs to promote cancer metastasis through its effects on the tumor microenvironment, enhanced invasive properties, and inhibition of immune cell function. Recent clinical evidence demonstrating a link between TGFbeta signaling and cancer progression is fostering interest in this signaling pathway as a therapeutic target. Anti-TGFbeta therapies are currently being developed and tested in pre-clinical studies. However, targeting TGFbeta carries a substantial risk as this pathway is implicated in multiple homeostatic processes and is also known to have tumor-suppressor functions. Additionally, clinical and experimental results show that TGFbeta has diverse and often conflicting roles in tumor progression even within the same tumor types. The development of TGFbeta inhibitors for clinical use will require a deeper understanding of TGFbeta signaling, its consequences, and the contexts in which it acts.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras.

            TGFbeta can override the proliferative effects of EGF and other Ras-activating mitogens in normal epithelial cells. However, epithelial cells harboring oncogenic Ras mutations often show a loss of TGFbeta antimitogenic responses. Here we report that oncogenic Ras inhibits TGFbeta signaling in mammary and lung epithelial cells by negatively regulating the TGFbeta mediators Smad2 and Smad3. Oncogenically activated Ras inhibits the TGFbeta-induced nuclear accumulation of Smad2 and Smad3 and Smad-dependent transcription. Ras acting via Erk MAP kinases causes phosphorylation of Smad2 and Smad3 at specific sites in the region linking the DNA-binding domain and the transcriptional activation domain. These sites are separate from the TGFbeta receptor phosphorylation sites that activate Smad nuclear translocation. Mutation of these MAP kinase sites in Smad3 yields a Ras-resistant form that can rescue the growth inhibitory response to TGFbeta in Ras-transformed cells. EGF, which is weaker than oncogenic mutations at activating Ras, induces a less extensive phosphorylation and cytoplasmic retention of Smad2 and Smad3. Our results suggest a mechanism for the counterbalanced regulation of Smad2/Smad3 by TGFbeta and Ras signals in normal cells, and for the silencing of antimitogenic TGFbeta functions by hyperactive Ras in cancer cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling.

              TGF-beta induces phosphorylation of the transcription factors Smad2 and Smad3 at the C terminus as well as at an interdomain linker region. TGF-beta-induced linker phosphorylation marks the activated Smad proteins for proteasome-mediated destruction. Here, we identify Nedd4L as the ubiquitin ligase responsible for this step. Through its WW domain, Nedd4L specifically recognizes a TGF-beta-induced phosphoThr-ProTyr motif in the linker region, resulting in Smad2/3 polyubiquitination and degradation. Nedd4L is not interchangeable with Smurf1, a ubiquitin ligase that targets BMP-activated, linker-phosphorylated Smad1. Nedd4L limits the half-life of TGF-beta-activated Smads and restricts the amplitude and duration of TGF-beta gene responses, and in mouse embryonic stem cells, it limits the induction of mesoendodermal fates by Smad2/3-activating factors. Hierarchical regulation is provided by SGK1, which phosphorylates Nedd4L to prevent binding of Smad2/3. Previously identified as a regulator of renal sodium channels, Nedd4L is shown here to play a broader role as a general modulator of Smad turnover during TGF-beta signal transduction.
                Bookmark

                Author and article information

                Contributors
                aooshima@snu.ac.kr
                jasonsjkim@snu.ac.kr
                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                23 January 2019
                February 2019
                : 110
                : 2 ( doiID: 10.1111/cas.2019.110.issue-2 )
                : 481-488
                Affiliations
                [ 1 ] Precision Medicine Research Center Advanced Institutes of Convergence Technology Suwon Korea
                [ 2 ] Graduate School of Convergence Science and Technology Seoul National University Suwon Korea
                Author notes
                [*] [* ] Correspondence

                Akira Ooshima, Precision Medicine Research Center, Advanced Institutes of Convergence Technology, Suwon, Korea.

                Email: aooshima@ 123456snu.ac.kr

                Seong-Jin Kim, Graduate School of Convergence Science and Technology, Seoul National University, Suwon, Korea

                Email: jasonsjkim@ 123456snu.ac.kr

                Author information
                https://orcid.org/0000-0002-2637-1219
                Article
                CAS13922
                10.1111/cas.13922
                6361575
                30589983
                795900a1-1384-4061-99c5-79dbb1ebf12e
                © 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 19 November 2018
                : 19 December 2018
                : 23 December 2018
                Page count
                Figures: 5, Tables: 0, Pages: 8, Words: 4834
                Funding
                Funded by: Korea Health Industry Development Institute
                Award ID: HI14C2640
                Categories
                Review Article
                Review Articles
                Custom metadata
                2.0
                cas13922
                February 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.5.8 mode:remove_FC converted:04.02.2019

                Oncology & Radiotherapy
                breast cancer,emt,metastasis,smad3,tgf‐β
                Oncology & Radiotherapy
                breast cancer, emt, metastasis, smad3, tgf‐β

                Comments

                Comment on this article